New brain protection strategies for infants with hypoxic-ischaemic encephalopathy

Annabel Greenwood, Jamie Evans, Elisa Smit

Research output: Contribution to journalReview article (Academic Journal)peer-review

2 Citations (Scopus)


Hypoxic ischaemic encephalopathy (HIE) occurs in 1.5–2/1000 births in developed countries and 26/1000 births in developing countries. Therapeutic cooling to a core temperature of 33.5°C for 72 h has become the mainstay of treatment for term infants with moderate and severe HIE with clinically proven improvements in both mortality and morbidity. This review article first explores current knowledge and limits of the use for therapeutic hypothermia, and then goes on to explore the potential new therapies that can provide additional neuroprotection. Currently researched neuroprotective treatments include pharmacological therapies (allopurinol, cannabinoids, erythropoietin, magnesium sulphate, melatonin, topiramate, and the noble gases xenon and argon), remote ischaemic post-conditioning, and the use of stem cells. The evidence available for these therapies and the current stage of their research are discussed.

Original languageEnglish
Pages (from-to)405-411
Number of pages7
JournalPaediatrics and Child Health (United Kingdom)
Issue number9
Early online date7 Jul 2018
Publication statusPublished - 1 Sep 2018


  • hypoxic ischaemic encephalopathy
  • neonatal encephalopathy
  • neuroprotection
  • neuroprotective agents
  • newborn
  • therapeutic hypothermia

Fingerprint Dive into the research topics of 'New brain protection strategies for infants with hypoxic-ischaemic encephalopathy'. Together they form a unique fingerprint.

Cite this